Effect of Pergolide Therapy on Semen Parameters in a Stallion With Pituitary Pars Intermedia Dysfunction by Ujvari, Sarah et al.
Accepted Manuscript
Effect of pergolide therapy on semen parameters in a stallion with pituitary pars
intermedia dysfunction
S. Ujvari, V. Gerber, H. Sieme, N. Fouché, D. Burger
PII: S0737-0806(17)30397-0
DOI: 10.1016/j.jevs.2017.07.007
Reference: YJEVS 2352
To appear in: Journal of Equine Veterinary Science
Received Date: 20 April 2017
Revised Date: 14 July 2017
Accepted Date: 16 July 2017
Please cite this article as: Ujvari S, Gerber V, Sieme H, Fouché N, Burger D, Effect of pergolide
therapy on semen parameters in a stallion with pituitary pars intermedia dysfunction, Journal of Equine
Veterinary Science (2017), doi: 10.1016/j.jevs.2017.07.007.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Effect of pergolide therapy on semen parameters in a stallion with pituitary pars 1 
intermedia dysfunction  2 
 3 
S. Ujvari1, V. Gerber1, H. Sieme2, N. Fouché1,§ and D. Burger1,§,* 4 
 5 
§
 Shared senior authorship 6 
 7 
1Swiss Institute of Equine Medicine, University of Bern and Agroscope, Switzerland, 2Clinic 8 
for Horses – Unit for Reproductive Medicine, University of Veterinary Medicine Hanover, 9 
Hanover, Germany 10 
 11 
*Corresponding author: dominik.burger@vetsuisse.unibe.ch 12 
Agroscope, Universität Bern Vetsuisse-Fakultät 13 
Institut suisse de médecine équine 14 
Les Longs Prés 15 
CH-1580 Avenches    16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
  25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Abstract 26 
A 23 year-old Warmblood stallion with pituitary pars intermedia dysfunction (PPID) was 27 
treated with 0.002 mg/kg body weight pergolide orally once a day, starting in July. Semen 28 
collections during five consecutive days each were performed before starting and at 90 days 29 
after initiation of the therapy in order to assess the effect of the therapy on semen volume, 30 
concentration, total sperm count, motility and viability. The only changes observed were 31 
lowered semen volume compensated by increased semen density resulting in an equal total 32 
sperm count. Possible causes for these observations include altered prolactin levels, the 33 
influence of season, or pergolide acting directly on the ejaculation process. This case report 34 
provides first evidence, that pergolide therapy in PPID may alter semen parameters, but these 35 
changes are unlikely to affect fertility. However this observation in a single individual must 36 
be confirmed with experiments on multiple stallions. 37 
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Introduction 41 
Pituitary pars intermedia dysfunction (PPID) or equine Cushing syndrome is an endocrine 42 
disorder which mostly occurs in aged horses without a breed predisposition [1-2]. 43 
Hypertrichosis is the pathognomonic sign of PPID (55% - 80% of cases) [1], but other 44 
clinical signs associated with PPID include polyuria and polydypsia, chronic infections, 45 
laminitis, catabolism of muscles i.e. in the back and abdominal region [2], as well as 46 
disturbances of the reproductive functions with impaired fertility [1, 3]. These reproductive 47 
problems have been observed in mares, namely inhibition of normal ovarian activity, small 48 
sized follicles, absence of a corpus luteum, flaccid uterus as well as problems to maintain a 49 
normal pregnancy [4]. Case reports suggest that pergolide treatment of PPID can restore 50 
reproductive function in those animals [4-5]. In contrast to these observations in mares, the 51 
effects of pergolide treatment on the male reproductive system have so far not been 52 
documented. In a recently published case report no abnormalities were found in routine 53 
semen examinations of a 21-year-old PPID-affected stallion and no histopathological 54 
alterations were seen in the testicles. However treatment effects of pergolide could not be 55 
investigated due to anticipated death of the stallion [6]. 56 
The pathogenesis of PPID is not fully understood. It is hypothesized that PPID mainly results 57 
from oxidative stress and neurodegeneration in the dopaminergic neurons of the 58 
hypothalamus causing a decrease in dopamine production. The loss of the negative control by 59 
dopamine in the pituitary pars intermedia leads to an excessive production of 60 
propiomelanocortin-derived peptides [5, 7]. It is still unknown which specific endocrine 61 
changes lead to which clinical signs observed in horses affected with PPID, and more 62 
specifically, to which potential disturbances of the reproductive system. Prolactin seems to 63 
play a major role in humans suffering from diseases associated with the pituitary gland, but 64 
whether similar effects are also present in horses with PPID is unknown [8-9].  65 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
In PPID, pergolide, a long-acting dopamine agonist, is the medical therapy of choice [3]. 66 
Positive response to medication is evidenced by improvement of clinical signs and a decrease 67 
of plasma adrenocorticotropic hormone (ACTH) concentration [3]. There is, to the authors’ 68 
knowledge, no information regarding the effect of pergolide on the equine male reproductive 69 
system. This report describes the case of a stallion with PPID and compares the sperm quality 70 
and quantity before and after initiation of a therapy with pergolide. 71 
 72 
Material and methods 73 
Animal, anamnesis, clinical/ endocrinological findings and treatment 74 
A 23 year old Holstein stallion weighing 571 kg was presented with signs of hypertrichosis 75 
and a history of delayed shedding of the winter coat. Furthermore, he showed slight axial 76 
musculature atrophy and a cresty neck. Plasma ACTH measurement was performed in 77 
February because of suspected PPID. A venous EDTA blood sample was collected and 78 
immediately centrifuged (3000g; 10 min) in a special EDTA-Plasma stabilisation tube 79 
(ACTHstab-Mikrogefäss, ALOMED, Radolfzell-Böhringen, Germany). The plasma was then 80 
collected and sent to the laboratory (ALOMED, Radolfzell-Böhringen, Germany), where 81 
plasma ACTH concentration was measured using chemiluminescence immunoassay.  82 
The ACTH plasma concentration was 87 pg/ml, suggesting a high probability for PPID in 83 
this horse [7, 10]. The stallion was treated with 0.002 mg/kg body weight pergolide 84 
(Prascend®, Boehringer Ingelheim, Basel, Switzerland) orally once a day starting the 18th 85 
July until his death 3 years later. A second blood analysis six months after initiation of 86 
pergolide therapy using the same approach revealed a plasma ACTH concentration (37 87 
pg/ml) within the normal range base on the laboratory references [10], but still slightly above 88 
the upper threshold described in the study of McGowan et al. in 2013 (29.7 pg/ml) [7]. 89 
 90 
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Semen evaluation 91 
Two semen evaluation series took place from 9th to 13th July before and from 15th to 19th  92 
October 90 days after initiation of the pergolide treatment in order to compare the effects of 93 
the medication on semen parameters. Before each semen evaluation series, semen collections 94 
were performed one time per day for five consecutive days in order to deplete and stabilize 95 
the extragonadal sperm reserves as described by Thompson et al. [11]. After a break of one 96 
day, semen was again collected daily once during five consecutive days, followed by a 97 
comprehensive semen evaluation of each ejaculate. 98 
Ejaculates were collected using a dummy and an artificial vagina (type Avenches, Swiss 99 
National Stud, Avenches, Switzerland). Immediately after collection and removal of the gel 100 
fraction, the volume of the ejaculate was determined using a graduated container, the sperm 101 
concentration and viability (integrity of the sperm plasma membrane) were evaluated using a 102 
nucleocounter (NucleoCounter® SP-100™ Sperm Cell Counter, ChemoMetec A/S, Allerød, 103 
Denmark [12]) and total sperm number was calculated. Total and progressive motility were 104 
assessed in 10 µl raw semen diluted with 20 µl INRA 96TM (IMV Technologies, L'Aigle, 105 
France) with a computer assisted sperm analyzer (HTM-IVOS, Version 12, Hamilton Thorn, 106 
Beverly, Massachusetts, USA) using a 20 µm standard count analysis chamber (Art. Nr. SC 107 
20-01-C, Leja, Nieuw-Vennep, Netherlands) and standardized threshold values for stallion 108 
semen.  109 
 110 
Statistics 111 
Statistical analysis was carried out using NCSS software (NCSS 2007, Statistical Solutions, 112 
Saugus, USA). Semen volume, concentration, total sperm count, motility and viability were 113 
normally distributed and parametric paired t-tests were performed in order to assess the 114 
effects of treatment. Results were expressed as means ± standard deviation (SD) of the 115 
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average recordings before and after treatment. Values were considered to be statistically 116 
significant at a probability level of P < 0.05.  117 
 118 
Results 119 
After 90 days of therapy, improved hair coat quality and body condition were observed. No 120 
adverse side effects were witnessed during the course of the treatment. The stallion did not 121 
exhibit any behavioral changes during semen collection. Results of the spermatological 122 
analysis are illustrated in Table 1. The volume of the ejaculates was significantly higher in 123 
the samples collected before pergolide treatment compared to the samples collected after 124 
initiation of the therapy (P = 0.003). Semen concentration showed a tendency to be increased 125 
during the therapy (P = 0.06), while the other parameters showed no changes.  126 
 127 
Discussion 128 
Adequate management of aged stallions is crucial for maintaining their reproductive capacity 129 
as long as possible. The present report describes standard variables of semen assessment in a 130 
single PPID-affected breeding stallion treated daily with pergolide for 90 days. Our 131 
observations indicate that the changes in semen parameters that occurred during the thirteen 132 
week treatment period are unlikely to affect reproductive capacity. The only alteration 133 
observed was a lowered semen volume compensated by an increased semen density leading 134 
to an equal total sperm count. 135 
Impaired female reproductive capacity associated with PPID has been reported [3-5], but the 136 
specific endocrine cause of this observation is unknown. Similarly, the effect of the treatment 137 
of choice, pergolide, on fertility, pregnancy and lactation has only been described in two 138 
reports of single cases [4, 13]. Fertility problems associated with PPID in aged stallions are 139 
much less recognized, likely since the number of stallions used in reproduction is much 140 
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smaller than that of mares. Nevertheless, there is strong interest in evaluating effects of the 141 
disease itself and the associated therapy on reproductive capacity of affected males [6]. 142 
PPID is a disease affecting the hypothalamic-pituitary-adrenal axis leading to alterations in 143 
the release of several hormones including dopamine, ACTH, melanocyte-stimulating 144 
hormone or corticotropin-like intermediate peptide [5]. Reproductive hormones like 145 
prolactin, gonadotropin-releasing-hormone (GnRH), luteinizing hormone (LH) or follicle 146 
stimulating hormone (FSH) produced in the pituitary gland or testosterone produced in the 147 
adrenal gland are all potentially altered in horses with PPID and these changes might result in 148 
a decreased reproductive capacity in aged mares and stallions. Furthermore, pergolide, a 149 
dopamine agonist used in the treatment of PPID, might also influence levels of those 150 
hormones, again potentially altering the reproductive capacity in stallions.  151 
In human medicine, signs of reduced reproductive capacity have been described in males 152 
with a similar disease called Cushing’s syndrome (loss of libido, loss of erectility, decreased 153 
testosterone level) [14]. In one case, high cortisol levels impaired testicular function and 154 
influenced testosterone concentrations [14]. In humans, pituitary adenomas often represent 155 
prolactinomas inducing hyperprolactinaemia [8]. The important role of prolactin in fertility is 156 
well documented: Prolactin acts as a modulator on the hypothalamus-pituitary-gonadal axis 157 
[15], and its secretion is regulated by the pituitary portal circulation through dopamine [8]. It 158 
has been reported in humans that high levels of prolactin have negative effects on 159 
testosterone levels through inhibition of GnRH leading to decreased LH and FSH secretions 160 
[15], and can impair spermatogenesis, but also decrease libido and provoke erectile 161 
dysfunction and prostate hyperplasia [8-9, 15]. Treatment with the dopamine type 2 (D2) 162 
selective-agonist cabergoline has been used to re-establish normal levels of prolactin [9, 15] 163 
and has been shown to provide a beneficial effect on the sperm quality, specifically regarding 164 
the number of spermatozoids and their motility [15].  165 
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Based on a study by Thomson et al. [11], prolactin also plays a role in stallion fertility, in 166 
particular regarding accessory gland functions. It seems to have an effect on the seminal 167 
ejaculate gel-free volume. The lower volume values observed in our case could therefore be 168 
explained by a decrease of prolactin blood levels. However, contrary to findings in humans, a 169 
previous study found no significant effects of the D2-agonist bromocriptine on spermatozoid 170 
numbers in horses [11]. Based on this observation, pergolide therapy would not be expected 171 
to influence spermatozoid numbers, at least not by way of an effect on prolactin. In men, 172 
results were evaluated after prolonged treatment, e.g. 12 – 24 months [15], and showed an 173 
earlier improvement of ejaculate volume and sperm count than of all other parameters [3]. In 174 
our case, semen quantity and quality was assessed after a comparatively shorter pergolide 175 
treatment interval. The observation period of 90 days was chosen because it largely 176 
encompassed the duration of spermatogenesis in stallions and the time of 6 to 8 weeks needed 177 
to observe clinical improvement [16-17]. 178 
A further explanation for the observed decrease of ejaculate volumes could be a direct 179 
influence of pergolide on the D2-receptor of the central or peripheral nervous system 180 
influencing the ejaculatory process [11]. Many mammalian (including equine) spermatozoids 181 
have also been shown to exhibit D2 receptors which are sensitive to dopamine and dopamine 182 
agonists [18-19]. According to different studies in human and equine semen, dopamine 183 
agonists have a negative influence on semen motility [18-19]. We cannot confirm such an 184 
effect in the single case we have documented.  185 
Finally, the changes that we have observed were associated with the pergolide treatment 186 
period, but pergolide may not be the cause of these alterations. The endocrine system is 187 
affected by many factors like environment, season, nutrition and age [20-22]. These variables 188 
could all influence the paracrine and autocrine modulation [21]. It has been demonstrated that 189 
during the breeding season stallions have increased testicular function [22-23]. In our case, 190 
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first sperm collection series was performed in July (summer and end of breeding season) 191 
while the second collection series took place in October (autumn and no breeding season). 192 
Observed decrease of semen volume and by trend higher concentration go in line with our 193 
reference values of 10 Warmblood stallions evaluated in a former study in the same stud farm 194 
(41.2 ml and 270.0 x 106 sp/ml in summer vs. 36.3 ml and 323.1 x 106 sp/ml in autumn [22]). 195 
This case report provides first evidence, that pergolide therapy in PPID may alter semen 196 
parameters, but these changes are unlikely to affect fertility. However this observation in a 197 
single individual must be confirmed with experiments on multiple stallions during different 198 
seasons of the year and variable treatment intervals In addition, it would be interesting to 199 
complement the variables reported here by also variations of prolactin, LH, FSH and 200 
testosterone. 201 
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 271 
 272 
Table 1: Summary of the means ± standard deviations (SD) of various semen parameters 273 
collected over a period of 5 days each prior and after 90 days of oral pergolide treatment in a 274 
stallion.     275 
 276 
Parameter Before pergolide  
treatment 
During pergolide 
treatment 
  
  mean ± SD mean ± SD   
Volume (ml) 62.2 9.4a 33.4 12.1b  
 
Concentration  
(x 106 sp/ml)  
139.6 36.9 236.0 90.20   
Total sperm count  
(x 106 sp) 
8’766 2’895 7’484 2’336   
Total motility (%) 83.8 6.4 87.6 2.6   
Progressive motility (%) 58.2 5.8 61.4 4.4   
Viability (%) 88.0 2.0 87.8 0.8   
       
Means with different superscripts (a, b) are significantly different (P < 0.05). 277 
 278 
